ライフサイエンスコーパス: glycoform

1 at platelet-VWF exists as a distinct natural glycoform.

2 s prepared by chemical synthesis as a single glycoform.

3 fy the Fc-glycan structures to a homogeneous glycoform.

4 associated with the level of the mature PC1 glycoform.

5 imolar reduction (20%-25%) of the mature PC1 glycoform.

6 ely related homologue (beta-hLH) as discrete glycoforms.

7 itions allowed profiling of all abundant mAb glycoforms.

8 entification of both targeted and unexpected glycoforms.

9 hesis of GM-CSF aglycone and two homogeneous glycoforms.

10 2/F3, respectively, to improve resolution of glycoforms.

11 for different cellular cofactors and PrP(C) glycoforms.

12 st, only mild effects were observed for CD45 glycoforms.

13 C-SIGN tetramer was similar for all antibody glycoforms.

14 glycosylation profile toward agalactosylated glycoforms.

15 m that can be further transformed into other glycoforms.

16 ical synthesis contains discrete homogeneous glycoforms.

17 n a given site are heterogeneous mixtures of glycoforms.

18 now addresses previously refractory antibody glycoforms.

19 ormation of the corresponding homogeneous Fc glycoforms.

20 peptides and HILIC for resolution of peptide glycoforms.

21 or binding of an array of homogeneous IgG-Fc glycoforms.

22 e glycoform as of the production of multiple glycoforms.

23 glycoforms more strongly than Man5 and Man6 glycoforms.

24 osylation comprising high mannose to complex glycoforms.

25 y of the relative quantitation of individual glycoforms.

26 cross a broad range of tumor-associated MUC1 glycoforms.

27 patients produce the full spectrum of IgA1 O-glycoforms.

28 ions can be optimized by generating specific glycoforms.

29 ll other sites in both species have sulfated glycoforms.

30 ylation but may differ in its exact range of glycoforms.

31 erminal GalNAc was detected in a minority of glycoforms.

32 ae substitutions, and differentiate isomeric glycoforms.

33 odies to produce homogeneous intact antibody glycoforms.

34 oforms of IgG1, including doubly fucosylated glycoforms.

35 omplex type, and low amounts of triantennary glycoforms.

36 ction of fully core-fucosylated high-mannose glycoforms.

37 nts with the characterization of 7 different glycoforms.

38 quantify, and determine the impact of major glycoforms.

39 system resulted in secretion of two distinct glycoforms: a proteoglycan substituted with a single cho

40 y expressed as a combination of isoforms and glycoforms after proteolytic removal of N- and C-termina

41 ct, or whether the presence of aberrant IgA1 glycoforms alone can produce IgAN.

42 h are isolated as highly complex mixtures of glycoforms, alpha-hGPH obtained by chemical synthesis co

43 ease core fucosylation and induce additional glycoform alterations on hepatocyte proteins.

44 nowledged in Remsima regulatory filings, our glycoform analysis and receptor binding results appear t

45 The CS glycoform analysis method was then applied to cartilage

46 T, while the synthetic Man(9)GlcNAc(2)-RNase glycoform and natural RNase B did not show CRT-binding a

47 The relative amounts of each glycoform and total site occupancy were quantified using

48 was investigated using native Skp1 acceptor glycoforms and a novel synthetic peptide containing GlcN

49 ich proved the presence of a large number of glycoforms and an unpredicted diversity of the ceramide

50 rain from the male index case expressed both glycoforms and exhibited both immunotypes.

51 e of naturally occurring coagulation protein glycoforms and inherited defects in carbohydrate attachm

52 th supporting MS2 evidence, of under-sampled glycoforms and of those that failed to be identified by

53 n is very demanding given the many different glycoforms and structural isomers that can exist on glyc

54 timized CID fragmentation enables DIA of IgG glycoforms and suggest that such workflow may enable qua

55 The observed glycoforms and their distribution compared favorably to

56 ogonal experimental measurements of N-linked glycoforms and total oxidation.

57 Thus, interactions between different PrPC glycoforms appear to control the efficiency of prion for

58 Among the most distinctive features of the glycoforms are (i) a dimethylated rhamnose as the cappin

59 y biological activities of plant-derived SM6 glycoforms are comparable to the human-cell-derived coun

60 All glycoforms are endocytosed and ameliorate the cholestero

61 Structurally well-defined IgG-Fc glycoforms are highly demanded for understanding the eff

62 lycosylated signaling peptides with multiple glycoforms are identified, including the first report of

63 s, while O-acetylated sialic acid-containing glycoforms are retained longer.

64 onformation of multiple antigens by a single glycoform as of the production of multiple glycoforms.

65 Mass spectrometry of the LOS glycoforms assembled by two of these lgt mutants indicat

66 lycosylation, we aimed to define the natural glycoforms associated with robust Fc-mediated antiviral

67 itates the differential analysis of distinct glycoforms associated with specific proteins at distinct

68 Also, glycoforms at Asn52 of hFSH are all complex type, wherea

69 The stochastic distribution of glycoforms at glycosylation sites is revealed.

70 lysis reveals the stochastic distribution of glycoforms at occupied sequons, and the latter provides

71 The efficient identification of these glycoforms at the glycopeptide level by mass spectrometr

72 e observed the highest microheterogeneity of glycoforms at the N187 site of HPX, absence of core fuco

73 ing due to the microheterogeneity (different glycoforms attached to one glycosylation site) and macro

74 press E-selectin ligands, but express a CD44 glycoform bearing alpha-2,3-sialyl modifications.

75 ively on the high-molecular-weight (125 kDa) glycoform bearing core-2-branched O-linked glycans.

76 -linked glycoforms from biantennary N-linked glycoforms bearing terminal sialic acid residues was ach

77 All glycoforms bind cholesterol, and sterol binding to NPC2

78 ffects of rebuilding this fence with smaller glycoforms by expressing HIV-1 pseudovirions from a prim

79 ssion by microarray or of lipopolysaccharide glycoforms by mass spectrometry.

80 This glycoform can be further extended by the addition of a s

81 Interestingly, the Fc glycoforms carrying an unusual bisecting sugar moiety su

82 s characterized individually, with about 500 glycoforms characterized per Env protein.

83 igands, the P-selectin glycoprotein ligand-1 glycoform "CLA," and CD43.

84 he expected changes in the quantity of major glycoforms compared to healthy controls.

85 CCS increments that correspond to changes in glycoform compositions.

86 both pharmaceutical proteins, with estimated glycoform concentrations analyzed ranging from 0.35 to 9

87 TN17, which expresses a deeply truncated LPS glycoform consisting of only two 3-deoxy-d-manno-octulos

88 The most abundant glycoform consists of nine neutral monosaccharide residu

89 6 indicated that the primary oligosaccharide glycoform contained four heptose and four hexose residue

90 analysis of glycan data in order to identify glycoforms contributing to disease.

91 experimental data for the identification of glycoforms contributing to disease.

92 ith FcgammaR-expressing cell lines, all 2G12 glycoforms demonstrated similar binding to FcgammaRI, Fc

93 s occurred in the relative levels of the two glycoforms depending on the cell type and whether overex

94 In contrast, two glycoforms derived from glycoengineered plants that lack

95 antitative yields and conserve the number of glycoforms detected.

96 ated by comparing the abundance of different glycoforms determined by mass spectrometry to that deter

97 When closely related glycoforms did not occur naturally, exoglycosidases were

98 These glycoforms differ from what has been reported so far in

99 In human cells, the constituent glycoforms differ mostly in numerous ways of extensions

100 structural basis for immunochemically based glycoform differences, we characterized the O-linked gly

101 oforms of RPTPzeta/phosphacan and that these glycoforms differentially decorate the surface of distin

102 uire the ability to target these transferrin glycoforms differently after preloading with exogenously

103 of CWD exhibited a distinct constellation of glycoforms distinguishable from that of sCJDMM1 in two-d

104 the impact of cell culture conditions on the glycoform distribution during process optimization studi

105 ese hormones are administered as mixtures of glycoforms due to limitations of biological methods in p

106 ancy of each glycosylation site by different glycoforms during biological or pathological processes.

107 ymes, resulting in heterogeneous mixtures of glycoforms, each with a distinct physiological activity.

108 version with typical heterogenous mammalian glycoforms (ED(50) = 11 mug) had similar potency to the

109 Usually, CS glycoforms exist, differing in sulfation position and ur

110 sential for the assembly of the complete LOS glycoform expressed by M. catarrhalis 7169.

111 The presence of glycoform families that differ only in branching and/or

112 r nucleotide substrates and appropriate Skp1 glycoforms, followed by chromatographic analysis of acid

113 tion content, resulting in a distribution of glycoforms for a chain bound to any given serine residue

114 ses and lead to the exploration of promising glycoforms for antibody therapeutics.Post-translational

115 Importantly, we identified more than 25 glycoforms for each product and observed glycoform popul

116 ool to guide the engineering of specific Env glycoforms for HIV vaccine design.

117 has led to the development of specific drug glycoforms, for example, monoclonal antibodies, with enh

118 was analyzed; on this protein, more than 300 glycoforms from 23 detected glycosylation sites were ide

119 ing three different dissociation methods, 23 glycoforms from all 5 corresponding glycopeptides were i

120 of complex tri- and tetraantennary N-linked glycoforms from biantennary N-linked glycoforms bearing

121 We purified alpha- and beta-antithrombin glycoforms from plasma of 2 homozygous L99F patients.

122 e bovine serum albumin coupled with a common glycoform (fucosylated glycan lacking the alpha1,3-linke

123 Interestingly, the galactose-masked glycoform Gal(1)Glc(1)Man(9)GlcNAc(2)-RNase also showed

124 The synthesis of a selectively modified glycoform Gal(1)Glc(1)Man(9)GlcNAc(2)-RNase was accompli

125 k to develop a synthetic route toward single-glycoform GM-CSF.

126 All of the glycoforms had similar binding to HER2/neu expressed on

127 Quantification of glycoform has previously been demonstrated using a multi

128 further clarified the roles of CD44 and its glycoform HCELL in hematopoietic processes, providing ke

129 00-kDa band, exclusively comprising the CD44 glycoform "HCELL." E-Ig reactivity was most prominent on

130 The data suggested a role for Env glycoform heterogeneity in the activation of the lineage

131 e similar contributions to both high and low glycoforms (HG- and LG-CD147).

132 ifferences between laboratories and improved glycoform identification by our laboratory using a pepti

133 Glycosylation is heterogeneous, with twelve glycoforms identified at six of the sites.

134 osidase gave the Glc(1)Man(9)GlcNAc(2)-RNase glycoform in excellent yield.

135 combinant human erythropoietin, revealing 74 glycoforms in a 60-min run.

136 Lectins bound to the unpurified gonadotropin glycoforms in distinct patterns consistent with glycan s

137 quantification result uncovers five abundant glycoforms in HCC, including 3 core-fucosylated (CF) for

138 rential, effects of 1 were observed for CD43 glycoforms in multiple hematopoietic cells.

139 valuable for identifying the different KCNE1 glycoforms in native cells and determining the roles N-

140 SWATH data independent quantification of IgG glycoforms in pooled plasma samples of patients with liv

141 howed decreased levels of biofilm-associated glycoforms in the NTHI 86-028NP luxS strain.

142 Mutant strains lack sialylated glycoforms in their LPS and are more sensitive to killin

143 ne resulted in production of the Man5GlcNAc2 glycoforms, in which more than 50% were core-fucosylated

144 d G2F glycoforms to well-defined homogeneous glycoforms, including a fully sialylated (S2G2F) glycofo

145 populations express a discrete subset of LOS glycoforms, including those containing phosphorylcholine

146 Moreover, the galectin-3-bound glycoform increased in cancer, suggesting a pathophysiol

147 as used as a substrate, recruitment of three glycoforms into PrP(Sc) was found to be proportional to

148 nd industry because no apparent bias for any glycoforms is observed.

149 e reduced heparin affinity of the alpha-L99F glycoform (K(D), 107.9 +/- 3nM) was restored in the beta

150 107.9 +/- 3nM) was restored in the beta-L99F glycoform (K(D), 53.9 +/- 5nM) to values close to the ac

151 colon carcinoma cell line expresses the CD44 glycoform known as hematopoietic cell E-/L-selectin liga

152 Consistent with this finding, 2G12 glycoforms lacking core fucose (and xylose) mediated hig

153 nt with this finding, plant-derived H10-03-6 glycoforms lacking core N-glycan residues mediated highe

154 ing assay indicated that the synthetic RNase glycoforms maintained essentially the same global confor

155 e glycomics platform were demonstrated using glycoform mixtures made from standard CS preparations.

156 production methods typically produce PTM or glycoform mixtures within which function is difficult to

157 A binds certain Man7, Man8, and Man9 RNase B glycoforms more strongly than Man5 and Man6 glycoforms.

158 relative abundance of individual fucosylated glycoforms normalized to the level of their nonfucosylat

159 Interestingly, the new triantennary glycan glycoform of antibody showed much higher affinity for ga

160 We speculated that the natural beta-glycoform of antithrombin might compensate for the effec

161 ntigen, and (3) fetuin (FET), the sialylated glycoform of ASF.

162 16D10 was raised against a pathological onco-glycoform of bile salt-dependent lipase isolated from th

163 Therefore, the mature glycoform of CASQ (GlcNAc(2)Man(1-4)) within the SR can

164 The major glycoform of CASQ (GlcNAc(2)Man(9)) found in the proxima

165 These findings establish that the HCELL glycoform of CD44 confers tropism to bone and unveil a r

166 , human HSPCs uniquely display a specialized glycoform of CD44 known as hematopoietic cell E-/L-selec

167 the hematopoietic cell E/L-selectin (HCELL) glycoform of CD44, which functions as a high-affinity E-

168 monoclonal antibody IIH6, which recognizes a glycoform of dystroglycan, also detects the zebrafish pr

169 the homogeneous core-fucosylated Man5GlcNAc2 glycoform of EPO in the FUT8-overexpressed HEK293S GnT I

170 , depends on a specific alpha-2,6-sialylated glycoform of IgG Fc to induce Interleukin 4 (IL-4) and S

171 a scFv antibody fragment specific for the Tn-glycoform of MUC1 had potent activity in preclinical mod

172 d a CAR that recognized cancer-associated Tn glycoform of MUC1, a neoantigen expressed in a variety o

173 and binds primarily to the highly acetylated glycoform of PNAG but is not protective against infectio

174 st have been shown to incorporate a specific glycoform of sialylated LOS within the biofilm matrix.

175 messenger RNA and protein, and the "mature" glycoform of sIgM.

176 3GlcNAc alpha1O-benzyl, or the corresponding glycoform of Skp1, was described previously in cytosolic

177 We show here that the gastric glycoform of TFF2 is a calcium-independent lectin, which

178 show that this novel E-selectin ligand is a glycoform of the heavy chain component of the enzyme mye

179 udy, we evaluated the ability of 2 different glycoforms of a chimerized antihuman CD137 mAb, an aglyc

180 For the glycoforms of a given glycopeptide or set of derivatized

181 Eight glycoforms of an O-linked glycopeptide from Nucleobindin

182 esized structurally well-defined homogeneous glycoforms of antibodies with different combinations of

183 a promising platform to produce homogeneous glycoforms of antibodies, but the broad application of t

184 HCC patients, comprised of 23 heterogeneous glycoforms of bi- and triantennary, core and terminal fu

185 oenzymatic synthesis of the monoglucosylated glycoforms of bovine ribonuclease (RNase) as specific li

186 engineered plants to generate four different glycoforms of H10-03-6, an Fcab with engineered HER2/neu

187 that site-specific differences exist between glycoforms of human and equine FSH.

188 ation of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms

189 glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) direct

190 rs of the Ig family, such as agalactosylated glycoforms of IgG and polymeric IgA.

191 w for quantitative analysis of site specific glycoforms of IgG based on data independent acquisition

192 MS methods for the analysis of site specific glycoforms of IgG.

193 of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 gly

194 nd we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycofo

195 ng various homogeneous, natural or synthetic glycoforms of IgG1-Fc for structure-function relationshi

196 ld proceed to completion to give homogeneous glycoforms of IgG1-Fc when an excess of oligosaccharide

197 ms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples o

198 Linear trendlines were observed for the glycoforms of individual N-linked glycopeptides, the deg

199 highly selective manner to tumor-associated glycoforms of MUC1.

200 lonal animal antibody raised to deacetylated glycoforms of PNAG and a fully human IgG1 monoclonal ant

201 dy that both bind to native and deacetylated glycoforms of PNAG mediated complement-dependent opsonic

202 and features quantitative yield, homogeneous glycoforms of produced antibodies and ADCs, compatibilit

203 roach for comparative analysis of sialylated glycoforms of proteins containing differentially branche

204 chment, leading to the formation of multiple glycoforms of proteins.

205 achieved and what involvement the different glycoforms of PrP have in these processes remain to be d

206 sistant bands in CWD, representing different glycoforms of PrP(Sc).

207 ty of polydopamine-immobilized Con A for the glycoforms of RNase B is significantly affected by sligh

208 ese antibodies define biochemically distinct glycoforms of RPTPzeta/phosphacan and that these glycofo

209 t instrumentation to the characterization of glycoforms of rt-PA.

210 Modulated glycoforms of sIgM are signal competent and could bind t

211 Additionally, glycoforms of the antibody charge variants were identifi

212 We have generated five different glycoforms of the broadly HIV-1-neutralizing mAb 2G12 in

213 with these N-glycopeptides, 53 compositional glycoforms of the hinge region O-glycopeptide were profi

214 in the production of fully core-fucosylated glycoforms of the oligomannose substrate Man5GlcNAc2, su

215 The glycoforms of the same parent peptide were also chromato

216 ing, the binding of galectin-3 to particular glycoforms of transferrin.

217 plasmon resonance chip that captures native glycoforms of two well known E-selectin ligands (CD44/he

218 lar dynamics simulations of various Asn(347) glycoforms of uncleaved CBG indicated that multiple Asn(

219 h uniform glycosylation and a higher potency glycoform offer promise as biodefense therapeutics.

220 However, in contrast to the HCELL glycoform on human hematopoietic progenitor cells, which

221 ing live cells, we converted the native CD44 glycoform on MSCs into hematopoietic cell E-selectin/L-s

222 Furthermore, no significant impact from the glycoform on the ionization properties of the glycopepti

223 Distinct glycoforms on the IgG crystallizable fragment (Fc) dicta

224 In addition to 12 novel AFP glycoforms, our quantification result uncovers five abun

225 n-beta allowed the assignment of at least 18 glycoforms, plus a variety of deamidation, succinimide,

226 25 glycoforms for each product and observed glycoform population differences, with afucosylated glyc

227 In a given physiological state, glycoform populations are reproducible; therefore, disea

228 nable deep characterization of heterogeneous glycoform populations.

229 High-mannose glycoform preferentially samples conformations that are

230 quantitation of the different compositional glycoforms present.

231 roteolytic digestion, they differed in their glycoform profiles and levels of proteinase K (PK)-sensi

232 This new quantitative glycoform profiling method with use of MALDI-TOF in posi

233 However, there was a major difference in glycoform ratio of PrP(Sc) between CWD and sCJDMM1 affec

234 s that control prion replication and PrP(Sc) glycoform ratio.

235 n barrier that controls replication rate and glycoform ratios and has broad implications.

236 peptide repeat insertions) and show that the glycoform ratios of PrP(Sc) associated with PRNP point m

237 e cell surface and the mechanisms of altered glycoform related with HCC.

238 However, measurement of low abundant glycoforms remains challenging in complex samples like s

239 osaccharide content analysis of this altered glycoform revealed an increase in glucosamine deposition

240 Capillary electrophoresis greatly improved glycoform separation for both released glycans and glyco

241 To achieve optimal glycoform separation, background electrolytes of low pH

242 The four glycoforms share a common core structure, and the differ

243 targeted for the examination of the protein glycoforms, simplifying the analysis without sacrificing

244 ion sites but not glycosylation occupancy or glycoform stoichiometry.

245 ave elucidated for the first time the native glycoform structures of the mouse UPIa receptor and thos

246 N-linked oligosaccharides and a core protein glycoform substituted with N-linked glycans but without

247 tive glycopeptides that carried a variety of glycoform substitutions, each of which was linked throug

248 ammaRIIIa binding, compared to the truncated glycoforms, suggesting a role of IgG1 Fc N-glycan in opt

249 geted mode, it identified more site-specific glycoforms than the more commonly used data-dependent ac

250 ceptor-binding activity, and an azido-tagged glycoform that can be further transformed into other gly

251 oforms, including a fully sialylated (S2G2F) glycoform that may gain anti-inflammatory activity, a no

252 i-inflammatory activity, a nonfucosylated G2 glycoform that showed significantly enhanced FcgammaIIIa

253 IV synthesized polySia selectively on a NRP2 glycoform that was characterized by the presence of sial

254 iofilms contain variants with sialylated LOS glycoforms that are essential to biofilm formation.

255 rent numbers of sialic acids but also intact glycoforms that differed by the number and extent of neu

256 By contrast, glycoforms that lacked core oligosaccharide modification

257 ach is characterized by a distinctive set of glycoforms that reflects the wide variation in the numbe

258 N-terminal sequencing of the core protein glycoform, the addition of benzyl-beta-d-xyloside, and a

259 utants as a chemically uniform (Man5GlcNAc2) glycoform, the individual effect of each mutation on Fcg

260 eins contain populations of subtly different glycoforms; therefore, with stricter orientation control

261 Here we found that this cancer-specific MUC1 glycoform, through engagement of Siglec-9, 'educated' my

262 The synthetic homogeneous Fc glycoforms thus provide a useful tool for elucidating ho

263 The binding of the synthetic IgG1-Fc glycoforms to the FcgammaIIIa receptor was also investig

264 ansformed from mixtures of G0F, G1F, and G2F glycoforms to well-defined homogeneous glycoforms, inclu

265 The presence of a fully functional beta-glycoform together with the activity retained by these v

266 R) binding studies with the synthetic IgG-Fc glycoforms unambiguously proved that the presence of a b

267 on also increases the thermostability of CBM glycoforms up to 16 degrees C, and a mannose disaccharid

268 enerally limited in their ability to resolve glycoforms using mobile phases that are compatible with

269 n, we overexpressed triadin-1 as a series of glycoform variants in non-muscle cell lines and neonatal

270 We compared these isotype and N-glycoform variants with commercially available palivizum

271 king the naturally occurring APC-beta plasma glycoform was found to exhibit superior PAR1 proteolysis

272 Accordingly, the beta-L99F glycoform was fully activated by heparin.

273 ding to a subset of highly glycosylated CD45 glycoforms was regulated by the C2GnT-1 glycosyltransfer

274 re acceptor molecules, forming the novel LPS glycoform we call MLPS.MLPS biosynthesis is dependent up

275 sequentially truncated high-mannose IgG1 Fc glycoforms, we found that the C'E loop and the Cgamma2-C

276 rofile of antibodies and HDX property of the glycoforms were also determined by accurate intact mass

277 These glycoforms were associated with enhanced Fc-mediated red

278 Because most relatives with abnormal IgA1 glycoforms were asymptomatic, additional cofactors must

279 Regarding the F(ab')2 domain, 8 glycoforms were detected and separated in three differen

280 Six non-fucosylated diantennary complex type glycoforms were detected on the Asn144-containing glycop

281 global snapshots of major cellular N-linked glycoforms were detected, including their tissue localiz

282 lycan heterogeneity as well as the ratios of glycoforms were determined at each site.

283 sites of Gal deficiency) in myeloma IgA1 HR glycoforms were identified (in all but one case uniquely

284 Thirteen distinct glycoforms were identified for the Asn340-containing tai

285 Mechanistically, CD43 glycoforms were unperturbed by peracetylated N-(3-acetyl

286 he peptides may lead to the misassignment of glycoforms when LC-MS/MS with electron-transfer dissocia

287 knockdown cell line was the pure Man5GlcNAc2 glycoform, whereas that produced from the FUT8-overexpre

288 expression of only one major oligosaccharide glycoform, which lacked the terminal galactose residue a

289 IVIG's Fc glycans into a fully sialylated Fc glycoform, which may possess significantly enhanced anti

290 The technology gave rise to the concept of glycoforms, which allow diversification of a protein's p

291 g for 19.7% of Remicade and 13.2% of Remsima glycoforms, which translated into a 2-fold reduction in

292 vailability of large quantities of this MUC1 glycoform will allow the evaluation of its efficacy as a

293 ffinities for crystalline cellulose, and the glycoform with a single mannose at each of three positio

294 c regression analyses showed that the IgG-Fc glycoform with fucosylation and fully galactosylation wa

295 Single erythropoietin (EPO) glycoforms with defined mature oligosaccharide structure

296 d separation and analysis of not only intact glycoforms with different numbers of sialic acids but al

297 ogy occurs infrequently leading to yet other glycoforms with short half-lives.

298 al of enabling access to native and designed glycoforms with site-selectivity and glycan homogeneity.

299 Interestingly, the glycoforms with small glycans at each site displayed hig

300 d in the identification of over 60 different glycoforms with up to nine sialic acids.